SOLA Biosciences lands $38M AMED grant for ALS gene therapy
What's the deal? SOLA Biosciences JapanDealroom has a profile for this one. Try Dealroom → has been awarded roughly US$46.2M over five years by the Japan Agency for Medical Research and Development (AMED)Dealroom has a profile for this one. Try Dealroom →. The grant, announced on June 5, 2026, will fund SOL-257, a gene therapy targeting amyotrophic lateral sclerosis (ALS). SOLA Japan is the wholly owned subsidiary of Boston-based SOLA BiosciencesDealroom has a profile for this one. Try Dealroom →.
Who's backing it? The program is supported by Curie.BioDealroom has a profile for this one. Try Dealroom →, an AMEDDealroom has a profile for this one. Try Dealroom →-registered venture capital firm, as lead investor, with UTEC (The University of Tokyo Edge Capital Partners) participating as a follow-on investor.
What's the endgame? SOL-257 uses SOLA's JUMP70 platform, which harnesses the cell's protein quality-control machinery to target misfolded proteins while sparing healthy ones. The therapy aims to restore the function of TDP-43, a protein that becomes misfolded and aggregated in motor neurons in roughly 97% of ALS cases. SOLA is positioning it as a potentially first-in-class, disease-modifying treatment.
Why now? ALS carries a high unmet medical need, and SOLA plans to advance SOL-257 toward human proof of concept in both the US and Japan. "For ALS patients and their families, time is extremely important," said Keizo Koya, founder and chief executive officer of SOLA.
SOLA Japan will act as the central development hub, coordinating with the US team and academic, clinical, and manufacturing partners globally. Chief operating officer Yuta Inokuchi said the award is a chance to "build a truly integrated Japan-U.S. development platform."
The signal: At roughly $38 million, the grant ranks in the 99th percentile among health-sector grant rounds in a sample of 6,612. That scale signals growing state-backed appetite for high-risk gene therapy bets and a push to knit Japanese and US drug development into a single pipeline.
Read more: prnewswire.com
Image credit: SOLA Biosciences
